NspA is a highly conserved membrane protein that is reported to elicit prot
ective antibody responses against Neisseria meningitidis serogroups A, B an
d C in mice (D. Martin, N. Cadieux, J, Hanel, and B. R. Brodeur, J. Exp. Me
d. 185:1173-1183, 1997). To investigate the vaccine potential of NspA, we p
roduced mouse anti-recombinant NspA (rNspA) antisera, which were used to ev
aluate the accessibility of NspA epitopes on the surface of different serog
roup B strains by an immunofluorescence flow cytometric assay and by suscep
tibility to antibody-dependent, complement-mediated bacteriolysis. Among 17
genetically diverse strains tested, 11 (65%) were positive for NspA cell s
urface epitopes and 6 (35%) were negative. All six negative strains also we
re resistant to bactericidal activity induced by the anti-rNspA antiserum.
In contrast, of the 11 NspA surface-positive strains, 8 (73%; P < 0.05) wer
e killed by the antiserum and complement. In infant rats challenged with on
e of these eight strains, the anti-rNspA antiserum conferred protection aga
inst bacteremia, whereas the antiserum failed to protect rats challenged by
one of the six NspA cell surface-negative strains. Neither NspA expression
nor protein sequence accounted for differences in NspA surface accessibili
ty, since all six negative strains expressed NspA in outer membrane prepara
tions and since their predicted NspA amino acid sequences were 99 to 100% i
dentical to those of three representative positive strains. However, the si
x NspA cell surface-negative strains produced, on average, larger amounts o
f group R polysaccharide than did the 11 positive strains (reciprocal geome
tric mean titers, 676 and 224, respectively; P < 0.05), which suggests that
the capsule may limit the accessibility of NspA surface epitopes. Given th
ese strain differences in NspA surface accessibility, an rNspA-based mening
ococcal B vaccine may have to be supplemented by additional antigens.